Radionuclide Therapy of HER2-Expressing Xenografts Using [<sup>177</sup>Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Radionuclide Therapy of HER2-Expressing Xenografts Using [<sup>177</sup>Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

ABY-027 is a scaffold-protein-based cancer-targeting agent. ABY-027 includes the second-generation Affibody molecule Z<sub>HER2:2891</sub>, which binds to human epidermal growth factor receptor type 2 (HER2). An engineered albumin-binding domain is fused to Z<sub>HER2:2891</sub&...

Full description

Bibliographic Details
Main Authors: Yongsheng Liu, Tianqi Xu, Anzhelika Vorobyeva, Annika Loftenius, Vitalina Bodenko, Anna Orlova, Fredrik Y. Frejd, Vladimir Tolmachev
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cancers
Subjects:
HER2
radionuclide therapy
Affibody molecule
lutetium-177
Online Access:https://www.mdpi.com/2072-6694/15/9/2409

Internet

https://www.mdpi.com/2072-6694/15/9/2409

Similar Items